Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 4:21 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 4,112 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Experimental 2 Clear all
Completed Phase 2 Interventional Results available

A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer

NCT01617668
View directory record Official record
Conditions
Breast Cancer
Interventions
LCL161, paclitaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Fayetteville, Arkansas • Los Angeles, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Nov 3, 2026, 4:21 PM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

Investigation of Psychedelic Effects in Psychoactive Substances

NCT06772753
View directory record Official record
Conditions
Psychedelic Effects in Healthy Volunteers
Interventions
Placebo, Psilocybin, Ketamine, Dextromethorphan (DXM), Dimethyltryptamine (DMT), Methylenedioxymethamphetamine (MDMA), Tetrahydrocannabinol (THC)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
25 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Nov 3, 2026, 4:21 PM EST
Withdrawn Not applicable Interventional Accepts healthy volunteers

Rescue Emetic Therapy for Children Having Elective Surgery

NCT01067677
View directory record Official record
Conditions
Post Operative Nausea and Vomiting, Rescue Emetic Therapy
Interventions
Metaclopramide, Ondansetron, diphenhydramine, Saline
Drug
Lead sponsor
Franklyn Cladis
Other
Eligibility
3 Years to 18 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Nov 3, 2026, 4:21 PM EST
Completed Early Phase 1 Interventional

Intravenous Plasma Treatment for Parkinson's Disease

NCT04202757
View directory record Official record
Conditions
Idiopathic Parkinson Disease
Interventions
[21CFR640.30] Plasma from 18 - 25 year old volunteer donors, Saline
Biological · Other
Lead sponsor
The Neurology Center
Other
Eligibility
45 Years to 90 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Nov 3, 2026, 4:21 PM EST
Completed Phase 2 Interventional Results available

Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers

NCT00004412
View directory record Official record
Conditions
Skin Ulcers, Sickle Cell Anemia
Interventions
Arginine Butyrate, Standard local care dressing
Drug · Other
Lead sponsor
Susan P. Perrine
Other
Eligibility
16 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Nov 3, 2026, 4:21 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Hybrid Type I Effectiveness-Implementation Trial of a Social Network Support Intervention

NCT05723653
View directory record Official record
Conditions
HIV Seropositivity
Interventions
Social Network Support Intervention
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 49 Years
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
7
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Nov 3, 2026, 4:21 PM EST
Completed Not applicable Interventional Results available

Texture Analysis for Postmenopausal Osteoporosis

NCT00145977
View directory record Official record
Conditions
Osteoporosis, Osteopenia
Interventions
Alendronate, Calcium Citrate, Vitamin D
Drug · Dietary Supplement
Lead sponsor
University of Chicago
Other
Eligibility
59 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Nov 3, 2026, 4:21 PM EST
Terminated Phase 3 Interventional Accepts healthy volunteers

Growth and Tolerance of Healthy Term Infants to a New Infant Formula

NCT01137877
View directory record Official record
Conditions
Healthy Term Infants
Interventions
Milk based infant formula powder, Investigational Infant Formula #1, Investigational Infant Formula #2, Human Milk
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
1 Day to 11 Days
Enrollment
399 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
20
States / cities
Little Rock, Arkansas • Mission Hills, California • Norwich, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2010 · Synced Nov 3, 2026, 4:21 PM EST
Not listed Phase 3 Interventional

Study of EBI-005 in Dry Eye Disease (DED)

NCT02405039
View directory record Official record
Conditions
Dry Eye
Interventions
EBI-005, Placebo
Drug
Lead sponsor
Eleven Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Birmingham, Alabama • Newport Beach, California • Hamden, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Nov 3, 2026, 4:21 PM EST
Completed Phase 1Phase 2 Interventional

Evaluation of Safety and Efficacy of realSKIN® (Skin Xenotransplant) for Complete Closure of Severe Burn Wounds

NCT03695939
View directory record Official record
Conditions
Deep Full-thickness Burn Injury (Disorder)
Interventions
realSKIN (skin xenotransplant), Human Cadaver Allograft
Biological
Lead sponsor
XenoTherapeutics, Inc.
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Augusta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Nov 3, 2026, 4:21 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Community Discussions and Social Participation

NCT07013357
View directory record Official record
Conditions
Social Connectedness, Community Engagement, Physical Wellbeing
Interventions
Virtual Community Intervention, Control
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Nov 3, 2026, 4:21 PM EST
Completed Phase 2 Interventional Results available

A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy

NCT02973100
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dulaglutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
38
States / cities
Glendale, California • Greenbrae, California • Huntington Park, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Nov 3, 2026, 4:21 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Studies of AQ-13, a Candidate Aminoquinoline Antimalarial, in Comparison With Chloroquine

NCT00323375
View directory record Official record
Conditions
Malaria
Interventions
AQ-13, Chloroquine (CQ) Treatment
Drug
Lead sponsor
Tulane University Health Sciences Center
Other
Eligibility
21 Years to 45 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2005
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Nov 3, 2026, 4:21 PM EST
Terminated Phase 2 Interventional Results available

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

NCT05846646
View directory record Official record
Conditions
Oligometastatic Disease
Interventions
IMSA101, Immune checkpoint inhibitor, PULSAR
Drug · Radiation
Lead sponsor
ImmuneSensor Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Irvine, California • Kansas City, Kansas • New Brunswick, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Nov 3, 2026, 4:21 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Comparison of the Pharmacokinetic Properties of ARN-75039 Tablets With Excipients to Neat ARN-75039 in Hydroxypropyl Methylcellulose (HPMC) Capsules in Healthy Adult Participants Under Fed Conditions

NCT06911242
View directory record Official record
Conditions
Healthy Volunteer, Pharmacokinetics After Oral Intake
Interventions
ARN-75039
Drug
Lead sponsor
Arisan Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Nov 3, 2026, 4:21 PM EST
Completed Early Phase 1 Interventional

Nitrate Supplementation and Cerebrovascular and Cognitive Function in Metabolic Syndrome

NCT05532423
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Beetroot Juice - Active, beetroot juice - Placebo
Drug
Lead sponsor
Penn State University
Other
Eligibility
55 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Nov 3, 2026, 4:21 PM EST
Terminated Phase 3 Interventional

Evaluation of an Oral Nutritional Supplement in Older Hospitalized Patients

NCT01477723
View directory record Official record
Conditions
Pneumonia
Interventions
Experimental Oral Nutritional Supplement
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
55 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
12
States / cities
Mobile, Alabama • Chicago, Illinois • Springfield, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Nov 3, 2026, 4:21 PM EST
Terminated Not applicable Interventional

Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability

NCT01241942
View directory record Official record
Conditions
Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis, Bronchiectasis, Sarcoidosis, Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency
Interventions
Steen Solution™, Conventional Lung Transplant
Device · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Nov 3, 2026, 4:21 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

An Evaluation of the Spectra Optia CMNC Collection Procedure

NCT02253160
View directory record Official record
Conditions
Healthy Apheresis Donors, Mononuclear (MNC) Cell Donors
Interventions
Spectra Optia CMNC, COBE Spectra MNC, Granulocyte-colony stimulating factor (G-CSF)
Device · Drug
Lead sponsor
Terumo BCT
Industry
Eligibility
18 Years to 50 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Cincinnati, Ohio • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Nov 3, 2026, 4:21 PM EST
Completed Not applicable Interventional

The Impact of Telemedicine on Orthopaedic Trauma Patients With Closed Fractures

NCT01991782
View directory record Official record
Conditions
Telemedicine, Fracture
Interventions
Telemedicine
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Nov 3, 2026, 4:21 PM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)

NCT01387282
View directory record Official record
Conditions
Cachexia, Non-Small Cell Lung Cancer
Interventions
Anamorelin HCl, Placebo
Drug
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Industry
Eligibility
18 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
14
States / cities
Corona, California • Fountain Valley, California • Glendale, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2017 · Synced Nov 3, 2026, 4:21 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Rapid Effects of a Biofield Patch on Antioxidant Status and Cellular Energy

NCT07314359
View directory record Official record
Conditions
Antioxidant Status
Interventions
Active dermal patch, Placebo dermal patch
Other
Lead sponsor
Natural Immune Systems Inc
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Klamath Falls, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Nov 3, 2026, 4:21 PM EST
Recruiting Phase 3 Interventional

Optimizing Pain Treatment in Children On Mechanical Ventilation

NCT06994442
View directory record Official record
Conditions
Mechanical Ventilation, Pediatric Acute Respiratory Failure, Analgesics, Opioid, Sedation and Analgesia
Interventions
Acetaminophen, Ketorolac, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
2 Months to 17 Years
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
Little Rock, Arkansas • Washington D.C., District of Columbia • Ann Arbor, Michigan + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 3, 2026, 4:21 PM EST
Completed Phase 1 Interventional

Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy

NCT01170286
View directory record Official record
Conditions
Peanut Allergy
Interventions
Whole peanut extract, Placebo formulation
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
6 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Willingboro, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Nov 3, 2026, 4:21 PM EST